Oxolamine

Summary

Oxolamine (CHEMBL1620875) is a phase-3 clinical-stage small molecule (ATC R05DB07); indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: R05DB07
• Indications: 1 condition
• Chemistry: 245.32 Da · C14H19N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1620875
Name	Oxolamine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	13738
ATC	R05DB07
Molecular formula	C14H19N3O
Molecular weight	245.32
InChIKey	IDCHQQSVJAAUQQ-UHFFFAOYSA-N

SMILES: CCN(CC)CCC1=NC(=NO1)C2=CC=CC=C2

IUPAC name: N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine

Also known as: AF-438 FREE BASE, Oksalamin, Oxolamina, Oxolamine, SKF 9976 FREE BASE, SKF-9976 FREE BASE, OXOLAMINE, OXOLAMINE CITRATE, oxolamine

Parent form; salt/anhydrous children: CHEMBL1448044

Patent coverage: 164 distinct patent families (477 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A, Histamine H3 receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).